Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

Shares of banks and financial services companies are trading higher as Treasury yields retreat and investors rotate out of AI-exposed stocks into sectors with more established cash flows and dividend prospects.

If You’d Invested $10,000 in AGNC Today, Here’s the Monthly Income You’d Collect at Its Now Much Higher 16.5% Yield

AGNC Investment's stock has tumbled nearly 30% from its 52-week high due to rising 10-year Treasury yields, pushing its dividend yield to 16.5%. A $10,000 investment would generate approximately $137 monthly in dividend income. However, the article warns that while the yield is attractive, AGNC carries significant risks including stock volatility and the potential for dividend cuts, requiring investors to have high risk tolerance.

Piper Sandler Maintains Overweight on AGNC Investment, Lowers Price Target to $10

Piper Sandler analyst Crispin Love maintains AGNC Investment (NASDAQ:AGNC) with a Overweight and lowers the price target from $12 to $10.

How Much Would You Need to Invest in These 4 High-Yield Stocks to Earn $1,000 a Month?

The article examines four high-yield dividend REITs that could generate $1,000 monthly passive income. AGNC and Annaly are mortgage REITs with yields exceeding 15% but face significant interest rate risk. Realty Income and Vici Properties are equity REITs investing in physical real estate with more sustainable dividends. An average investment of approximately $103,941 across all four stocks would be needed to achieve $12,000 annual dividend income.

Why Is Arcutis Biotherapeutics Stock Surging Thursday?

Cantor Fitzgerald initiated Arcutis (ARQT) at Overweight with a $48 target, citing Zoryve's potential for $3.5B in peak sales.

Arcutis Biotherapeutics shares are trading higher after Cantor Fitzgerald initiated its coverage on the stock with an Overweight rating and announced a price target of $48.